Azitra Inc (AZTR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Azitra Inc (AZTR) has a cash flow conversion efficiency ratio of -0.761x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.89 Million) by net assets ($3.80 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. View Azitra Inc (AZTR) stock price for real-time trading data and today's change.
Azitra Inc - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Azitra Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see Azitra Inc stock valuation for the company's overall valuation and market capitalisation.
Azitra Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Azitra Inc ranked by their cash flow conversion efficiency. Also see AZTR total asset value for a full breakdown of the balance sheet.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Halo Technologies Holdings Ltd
AU:HAL
|
0.345x |
|
WestKam Gold Corp
V:WKG
|
0.023x |
|
Expion360 Inc
NASDAQ:XPON
|
-0.307x |
|
Coloseum Holding a.s.
PR:COLOS
|
N/A |
|
Beam Communications Holdings Ltd
AU:BCC
|
0.476x |
|
AEST.MED.INT.HLD.SP.ADR/3
F:3FMA
|
N/A |
|
Ostrom Climate Solutions Inc
V:COO
|
-0.097x |
|
British Smaller Companies Vct Plc
LSE:BSV
|
-0.001x |
Annual Cash Flow Conversion Efficiency for Azitra Inc (2021–2025)
The table below shows the annual cash flow conversion efficiency of Azitra Inc from 2021 to 2025. Review Azitra Inc free cash flow to debt ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $3.80 Billion | $-11.22 Million | -0.003x | +99.83% |
| 2024-12-31 | $5.70 Million | $-10.18 Million | -1.787x | +29.29% |
| 2023-12-31 | $2.91 Million | $-7.36 Million | -2.527x | -1197.56% |
| 2022-12-31 | $-36.26 Million | $-8.35 Million | 0.230x | -26.46% |
| 2021-12-31 | $-25.77 Million | $-8.07 Million | 0.313x | -- |
About Azitra Inc
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S. epidermidis that is in a Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer pat… Read more